Piia K Rannanheimo1, Pekka Tiittanen2, Juha Hartikainen3, Arja Helin-Salmivaara2, Risto Huupponen4, Jussi Vahtera5, Maarit Jaana Korhonen6. 1. Department of Pharmacology, Drug Development and Therapeutics, University of Turku, Turku, Finland; Finnish Medicines Agency, Kuopio, Finland. 2. Department of Pharmacology, Drug Development and Therapeutics, University of Turku, Turku, Finland. 3. Heart Center, Kuopio University Hospital, School of Medicine, University of Eastern Finland, Kuopio, Finland. 4. Department of Pharmacology, Drug Development and Therapeutics, University of Turku, Turku, Finland; Clinical Pharmacology Unit, Tykslab, Turku University Hospital, Turku, Finland. 5. Department of Public Health, University of Turku, Turku, Finland. 6. Department of Pharmacology, Drug Development and Therapeutics, University of Turku, Turku, Finland. Electronic address: maarit.korhonen@utu.fi.
Abstract
OBJECTIVES: To assess the extent to which adherence to statins is associated with the incidence of cardiovascular (CV) events and all-cause mortality in the primary prevention of CV diseases and whether different analytical approaches influence the observed associations. METHODS: This population-based cohort study used data from Finnish registers. The cohort included 97,575 new statin users aged 45 to 75 years in 2001 to 2004 with no CV diseases at baseline. Exposure was defined as adherence to statins (proportion of days covered [PDC]). The primary outcome was any CV event or death during a 3-year follow-up. Different analytical approaches, including multivariable-adjusted Cox regression, inverse probability weighting with time-varying adherence, and propensity score calibration, were used. RESULTS: During the first year of follow-up, 53% displayed good (PDC ≥80%), 26% had intermediate (PDC 40%-79%), and 21% exhibited poor (PDC <40%) adherence. After adjustment for sociodemographic and clinical covariates, a 25% relative risk reduction (hazard ratio [HR] 0.75; 95% confidence interval [CI] 0.71-0.79) was observed in the rate of any CV event or death among good versus poor adherers. Good adherers also had a lower incidence than poor adherers of acute coronary syndrome (HR 0.56; 95% CI 0.49-0.65) and acute cerebrovascular disease events (HR 0.67; 95% CI 0.60-0.76). The different analytical approaches achieved comparable results for all the outcomes. CONCLUSIONS: The incidence of CV events and mortality was higher in poor versus good adherers. Different analytical methods that took into account changes in adherence and confounding at baseline did not appreciably affect the results.
OBJECTIVES: To assess the extent to which adherence to statins is associated with the incidence of cardiovascular (CV) events and all-cause mortality in the primary prevention of CV diseases and whether different analytical approaches influence the observed associations. METHODS: This population-based cohort study used data from Finnish registers. The cohort included 97,575 new statin users aged 45 to 75 years in 2001 to 2004 with no CV diseases at baseline. Exposure was defined as adherence to statins (proportion of days covered [PDC]). The primary outcome was any CV event or death during a 3-year follow-up. Different analytical approaches, including multivariable-adjusted Cox regression, inverse probability weighting with time-varying adherence, and propensity score calibration, were used. RESULTS: During the first year of follow-up, 53% displayed good (PDC ≥80%), 26% had intermediate (PDC 40%-79%), and 21% exhibited poor (PDC <40%) adherence. After adjustment for sociodemographic and clinical covariates, a 25% relative risk reduction (hazard ratio [HR] 0.75; 95% confidence interval [CI] 0.71-0.79) was observed in the rate of any CV event or death among good versus poor adherers. Good adherers also had a lower incidence than poor adherers of acute coronary syndrome (HR 0.56; 95% CI 0.49-0.65) and acute cerebrovascular disease events (HR 0.67; 95% CI 0.60-0.76). The different analytical approaches achieved comparable results for all the outcomes. CONCLUSIONS: The incidence of CV events and mortality was higher in poor versus good adherers. Different analytical methods that took into account changes in adherence and confounding at baseline did not appreciably affect the results.
Authors: Kevin A Hommel; Meghan E McGrady; James Peugh; George Zacur; Katherine Loreaux; Shehzad Saeed; Elizabeth Williams; Lee A Denson Journal: Inflamm Bowel Dis Date: 2017-09 Impact factor: 5.325
Authors: Jo L Byrne; Helen M Dallosso; Stephen Rogers; Laura J Gray; Ghazala Waheed; Prashanth Patel; Pankaj Gupta; Yvonne Doherty; Melanie J Davies; Kamlesh Khunti Journal: BMC Med Date: 2020-07-27 Impact factor: 8.775
Authors: Piia Lavikainen; Arja Helin-Salmivaara; Mervi Eerola; Gang Fang; Juha Hartikainen; Risto Huupponen; Maarit Jaana Korhonen Journal: BMJ Open Date: 2016-06-03 Impact factor: 2.692
Authors: Johnny W Bai; Geneviève Boulet; Elise M Halpern; Leif E Lovblom; Devrim Eldelekli; Hillary A Keenan; Michael Brent; Narinder Paul; Vera Bril; David Z I Cherney; Alanna Weisman; Bruce A Perkins Journal: Cardiovasc Diabetol Date: 2016-01-25 Impact factor: 9.951
Authors: Moneeza K Siddiqui; Cyrielle Maroteau; Abirami Veluchamy; Aleksi Tornio; Roger Tavendale; Fiona Carr; Ngu-Uma Abelega; Dan Carr; Katyrzyna Bloch; Par Hallberg; Qun-Ying Yue; Ewan R Pearson; Helen M Colhoun; Andrew D Morris; Eleanor Dow; Jacob George; Munir Pirmohamed; Paul M Ridker; Alex S F Doney; Ana Alfirevic; Mia Wadelius; Anke-Hilse Maitland-van der Zee; Daniel I Chasman; Colin N A Palmer Journal: Eur Heart J Date: 2017-12-21 Impact factor: 35.855